Transplant drugs made by Roche (CellCept) and Novartis (Myfortic) are being investigated by the Food and Drug Administration (FDA) to determine if they increase the risk of a neurological disease called progressive multifocal leukoencephalopathy. The disease attacks the brain and central nervous system. Symptoms include vision problems, loss of coordination and memory loss.
 
The drugs are used to avoid rejection in transplant recipients.

This article originally appeared in the May 2008 issue of Kidney Transplant Today.